Company Shares of Sanofi (NYSE:SNY) Drops by -2.25%

Sanofi (NYSE:SNY) has risen sharply, recording gains of 3.65% in the past 4 weeks. However, the stock has corrected -2.25% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 2.01% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

The company shares have dropped -21.59% from its 1 Year high price. On Aug 10, 2015, the shares registered one year high at $54.98 and the one year low was seen on Jun 16, 2016. The 50-Day Moving Average price is $40.34 and the 200 Day Moving Average price is recorded at $40.76.

The stock has recorded a 20-day Moving Average of 2.21% and the 50-Day Moving Average is 1.91%.


Sanofi (NYSE:SNY): On Fridays trading session , Opening price of the stock was $41.12 with an intraday high of $41.2. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $40.82. However, the stock managed to close at $40.85, a loss of 0.34% for the day. On the previous day, the stock had closed at $40.99. The total traded volume of the day was 1,317,957 shares.

Sanofi SA is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company is organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. The Company invests in emerging markets, diabetes solutions, vaccines, consumer health care, animal health, genzyme and other products. The emerging markets platform includes products from all three of the Companys principal activities. Under the Companys Pharmaceuticals business, products are grouped into the key fields of diabetes solutions, rare diseases, multiple sclerosis, oncology, thrombosis and cardiovascular disease prevention, nephrology and bio-surgery. The Human Vaccines activity is operated through Sanofi Pasteur. The Animal Health activity is carried out through Merial.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.